(Q40554269)

21 September 2017

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer (English)

1 reference

21 September 2017

1 reference

1 reference

Mark D Pegram

1

1 reference

21 September 2017

Gottfried E Konecny

2

1 reference

21 September 2017

Carminda O'Callaghan

3

1 reference

21 September 2017

Malgorzata Beryt

4

1 reference

21 September 2017

Richard Pietras

5

1 reference

21 September 2017

Dennis J Slamon

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Journal of the National Cancer Institute

21 September 2017

1 reference

21 September 2017

96

1 reference

21 September 2017

10

1 reference

21 September 2017

739-749

1 reference

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

21 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

A model-based approach for assessing in vivo combination therapy interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Computerized determination of growth kinetic curves and doubling times from cells in microculture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Overexpression of the c-erbB-2 protein in human breast tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

Clinical pharmacokinetics of docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH131

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH131

1 reference

21 September 2017

1 reference